Advertisement: Mogrify mid banner
Advertisement: EY Mid banner
Advertisement mid banner S-Tech 1
Advertisement: Cambridge Network mid banner
Mid banner advertisement: BDO
Advertisement: Howard Group mid banner
Advertisement – Charles Stanley mid banner
Advertisement: Hewitsons mid banner
CBM light up lives mid banner advert
Advertisement: Kao Data Centre mid banner
RealVNC mid banner careers
Advertisement: EBCam mid banner
Advertisement: RSM
Advertisement: Simpsons Creative
ARM Innovation Hub
Barr Ellison Solicitors – commercial property
3 June, 2013 - 05:48 By News Desk

Cannabis-based drugs firm surges into profit

GW Pharmaceuticals CEO Justin Gover

GW Pharmaceuticals, the Cambridge UK medical technology business whose products are based on cannabis, has turned a 2012 first half loss into a 2013 H1 profit.

Total revenue for the six months to March 31 was £12.9m compared to £11.1m at the same stage last year. Net profit after tax was £0.1m compared to a loss of £3.2m in 2012.Cash and cash equivalents at period-end were £27.9m compared to £29.3m at September 30. The company raised an additional £18.2m from a NASDAQ IPO after the end of the trading period.CEO Justin Gover said: “GW has made significant progress in the year to date. Most notably, we recently successfully completed a Nasdaq listing and initial public offering to US investors.

“We believe that this represents a significant corporate milestone for GW. With Sativex® advancing through Phase 3 trials in the US for cancer pain, commercialisation continuing in Europe and other parts of the world, four new clinical trials commencing in a highly promising cannabinoid product pipeline, and a strong balance sheet, we are very excited about the next phase in our company’s evolution.”

Add new comment

Newsletter Subscription

Stay informed of the latest news and features